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Background: Periodic breathing (PB) during sleep and exercise in heart failure (HF) is related to respi-
ratory acid-base status, CO2 chemosensitivity, and temporal dynamics of CO2 and O2 sensing. We studied
inhaled CO2 and acetazolamide to alter these factors and reduce PB.
Methods and Results: We measured expired and arterial gases and PB amplitude and duration in 20 HF
patients during exercise before and after acetazolamide given acutely (500 mg intravenously) and pro-
longed (24 hours, 2 g orally), and we performed overnight polysomnography. We studied CO2 inhalation
(1%e2%) during constant workload exercise. PB disappeared in 19/20 and 2/7 patients during 2% and 1%
CO2. No changes in cardiorespiratory parameters were observed after acute acetazolamide. With pro-
longed acetazolamide at rest: ventilation þ2.04 6 4.0 L/min (P 5 .001), tidal volume þ0.11 6 1.13 L
(P 5 .003), respiratory rate þ1.24 6 4.63 breaths/min (NS), end-tidal PO2 þ4.62 6 2.43 mm Hg
(P 5 .001), and end-tidal PCO2 2.59 6 9.7 mm Hg (P ! .001). At maximum exercise: Watts 10%
(P ! .02), VO2 61 6 109 mL/min (P 5 .04) and VCO2 101 6 151 mL/min (P ! .02). Among 20
patients, PB disappeared in 1 and 7 subjects after acute and prolonged acetazolamide, respectively. PB
was present 80% 6 26, 65% 6 28, and 43% 6 39 of exercise time before and after acute and prolonged
acetazolamide, respectively. Overnight apnea/hypopnea index decreased from 30.8 6 83.8 to 21.1 6 16.9
(P 5 .003).
Conclusions: In HF, inhaled CO2 and acetazolamide reduce exercise PB with additional benefits of acet-
azolamide on sleep PB. (J Cardiac Fail 2014;20:278e288)
Key Words: Oscillatory ventilation, cardiopulmonary exercise test, polysomnography.Nocturnal and daytime periodic breathing (PB) in pa-
tients with moderate to severe chronic heart failure (HF)
is not uncommon and is independently predictive of earlier
mortality.1 This is true also for PB during exercise or exer-
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278been attributed to a variety of factors, including reduced
cardiac output resulting in an increased transit time of
blood from the pulmonary vasculature to the central and pe-
ripheral chemoreceptors, low lung volume, pulmonary
congestion, and augmented peripheral chemoreceptor
sensitivity leading to a lower eupneic (baseline) PaCO2
and a narrowing of the difference between the eupneic
PaCO2 and the apneic (or hypoventilatory) PaCO2
threshold.3 Notably, a central hypothesis for PB genesis
has also been proposed. This hypothesis is based on a
derangement of the vasomotor rhythm which modulates
ventilation either indirectly through blood flow modulation
or directly through central irradiation to the respiratory
centers.4e6
We have previously shown that addition of 250 mL and
500 mL of added external dead space reduced PB during
exercise in HF patients. This was most evident as the nadir
tidal volume (Vt) of each cycle approached the peak Vt,7
supportive of the idea that lung volume may be a factor.
Yet as a result of the added dead space, end-tidal PCO2
Fig. 1. Flow-chart of the tests performed. CPET, cardiopulmonary
exercise test; ABG, arterial blood gas test.
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(PetCO2) rose and we could not rule out suppression of PB
by an increase in the eupneic to apneic PCO2 difference.
Others have shown in HF patients that inspiration of low
concentrations of CO2 (3%) reduces PB or Cheyne-Stokes
respiration by this same mechanism.8e10 A third and inde-
pendent means to possibly alter the eupneic-apneic PCO2
difference favorably is by administration of acetazolamide,
a carbonic anhydrase (CA) inhibitor that acts by several
mechanisms to reduce PB during sleep at high altitude11,12
and in those with HF.13,14 In a small study of 12 patients
with HF, Fontana et al14 found that low-dose acetazolamide
(250 mg twice a day) for 4 days did not eliminate PB during
exercise in the 50% of patients who displayed the phenom-
enon, although it was effective in the whole group in
reducing the nocturnal and diurnal apnea-hypopnea indexes.
Our aims in the present study were to measure during
exercise in HF patients with an acetazolamide dose capable
of altering both peripheral and central CO2 chemosensitiv-
ity.15 To do so, we studied the drug effect after an acute
intravenous administration (500 mg) and compared it
with the response following 3 oral doses over 24 hours
(500 mg every 8 hours). The difference in the 2 dosing reg-
imens was to determine whether the suppression of PB by
acetazolamide is due to its effects on chemoreceptor and
red cell CA inhibition (acute administration) independently
from its known stimulant effect on ventilation (VE) arising
from the metabolic acidosis of renal CA inhibition that re-
quires several hours to develop and 12e24 hours to be fully
established (prolonged administration). Additionally, we
sought to compare the acetazolamide effects with those of
low concentrations of inhaled CO2 (1%e2%) able to
generate roughly the same small magnitude of tissue hyper-
capnia occurring from inhibition of red cell and vascular
endothelial cell CA with acetazolamide.12Materials and Methods
We studied 20 consecutive patients with HF (New York Heart
Association [NYHA] functional classification IIeIII) and PB dur-
ing exercise. These patients belong to the cohort of our HF clinic,
who undergo routine follow-up which includes clinical and labo-
ratory evaluations, echocardiography, spirometry, and cardiopul-
monary exercise test (CPET). PB was defined as a cyclic
fluctuation of ventilation present at rest and during exercise,
with amplitude swings O30% of the mean VE, O15% for
$60% of incremental exercise duration.16 The protocol was
approved by our Institutional Ethics Committee (ClinTrials.gov
NCT00517426), and written informed consent was obtained
from each patient.
Study inclusion criteria were evidence of HF in stable clinical
conditions, LVEF !40%, PB during exercise, and age 18e80
years. Study exclusion criteria were presence of unstable angina,
NYHA functional class IV, recent (!6 mo) myocardial infarction,
severe valvular disease, severe obstructive or restrictive lung dis-
ease (1-second forced expiratory volume or functional vital capac-
ity !60% of predicted value), symptomatic peripheral vascular
disease or orthopedic problems that could limit exerciseperformance, and neurologic diseases, such as dementia, stroke,
or cerebrovascular disease.
To select patients for this study, we performed the following
tests in patients regularly followed in our HF clinic: cardiac ultra-
sound evaluation to determine left ventricular volume and ejection
fraction (LVEF), standard spirometry to exclude severe lung dis-
ease, and maximal ramp (5e10 W/min) symptom-limited CPET
for familiarization purposes and to select patients with PB during
exercise. During the CPET performed with a cycle ergometer, pa-
tients breathed through a mouthpiece connected to a mass flow-
meter. We used a personalized ramp protocol aimed at achieving
a maximal effort in w10 minutes. If this was not obtained, the
ramp protocol was adjusted accordingly in a 2nd test to achieve
a 10-minute duration. The loaded exercise was preceded by a
few minutes (O5 min) of resting ventilation measurements and
by a O3-minute period of unloaded pedaling. VE, oxygen con-
sumption (VO2), and carbon dioxide production (VCO2; V-max;
Sensormedics, Yorba Linda, California) were measured breath
by breath. A 12-lead electrocardiogram was recorded continuously
to derive heart rate and monitor for ischemic or ectopic changes.
During exercise, arterial pressure was measured every 2 minutes
by sphygmomanometer. All patients meeting the inclusion/exclu-
sion criteria underwent 3 days of testing. Figure 1 is a consort di-
agram of the experimental protocol.Day 1
On the 1st study day, patients performed a ramp CPET (as
defined above) with arterial blood gas samples taken at rest and
every 2 minutes during exercise via a small catheter in the radial
artery. After a sufficient period of rest (6 h), they underwent a con-
stant workload CPET for 12 minutes at 25% of their maximal pre-
viously determined work load. In the unloaded pedaling period,
the subjects breathed ambient air. In the first 4 minutes (stage 1)
of loaded pedaling they breathed ambient air, then 2% CO2/21%
O2 balanced with N2 during the next 4 minutes (stage 2), and
then ambient air again for the last 4 minutes (stage 3). Whenever
possible the constant workload CPET was repeated at least 1 hour
later with 1% CO2 at stage 2. During constant workload CPET
Fig. 2. Example of a constant workload test with disappearance of
periodic breathing during 2% CO2 inhalation. Vt, tidal volume.
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inspiratory and expiratory valves. The former was connected to
a large low pressure balloon filled with room air or the 1% or
2% CO2 mixture, as required by the protocol. Arterial blood sam-
ples were collected at the end of each stage. In 7 patients randomly
selected, the constant work test was repeated with the use of a 1%
CO2 mixture with the same temporal sequence. That night, all pa-
tients underwent an overnight respiratory monitoring study with
measurement of nasobuccal air flow, chest and abdominal move-
ment, oxygen saturation (SaO2), and heart rate with the use of
the Pamela Sleep Recorder (Medatecs, Brussels, Belgium).
Day 2
The next day, patients repeated the ramp CPET with arterial
blood gas samples following the day 1 protocol 1 hour after the
administration of 500 mg intravenous acetazolamide. In this pro-
tocol, the addition of inhaled CO2 in the 2nd phase was not stud-
ied. Thereafter, treatment with 500 mg acetazolamide every 8
hours was started.
Day 3
On the 3rd day the patients again underwent the same testing as
on day 2, but now after having received a total of 2 g acetazol-
amide (500 mg intravenously on day 1, followed by 3 500 mg
oral doses every 8 hours). Then overnight respiratory event moni-
toring was again performed.
We analyzed the following ramp CPET parameters performed
under the 3 different conditions (basal, and after ‘‘acute’’ and
‘‘prolonged’’ acetazolamide administration): VO2 (mL/min),
VO2/kg (mL min
1 kg1), VCO2 (mL/min), VE (L/min), PetCO2
(mm Hg), end-tidal O2 (PetO2; mm Hg), Vt (L), respiratory rate
(RR; breaths/min), heart rate (HR; beats/min), O2 pulse (VO2/
HR), work load achieved (W), and exercise tolerance (min).
Peak exercise HR and gas exchange data were averaged over
30-second intervals. During exercise, we also recorded the kinetics
of VE/VCO2 (ventilatory equivalents for CO2) and the VO2/work
relationships. The PB duration was determined from the beginning
of exercise (% of total exercise duration); number of cycles of PB
during exercise, length of the first cycle of PB during exercise (s),
VE and Vt measurements at peak and nadir of PB cycles (mean of
the first 3 cycles), and maximum value of Vt and VE during exer-
cise and at PB disappearance were also determined. Arterial blood
gas analysis included measurement of pH, PO2, PCO2, HCO3
,
and SaO2%.
During constant work rate CPET, we analyzed the following pa-
rameters at the end of the 4th, 8th, and 12th minutes: presence of
PB during each exercise stage, peak and nadir values of VE and
Vt, mean values during CO2 inhalation if PB disappeared, peak
and nadir of the cycles if not, and the maximum values of Vt
and VE, along with arterial blood gas values.
To determine the disappearance of PB during both ramp and
constant work rate exercise tests, we considered Vt as reference
variable and defined PB cessation when the amplitude of VE
swings was !10%. To do so, data were evaluated by visual in-
spection and graphically measured. An example is presented in
Figure 4 (bottom).
We analyzed the sleep respiratory events, recorded both in the
basal condition and after prolonged administration of acetazol-
amide with the use of the following criteria. Apnea was defined
as cessation of air flow that lasted $10 seconds. Central apnea
was identified by air flow cessation together with absence ofthoraco-abdominal movements, whereas obstructive apnea was
defined as air flow cessation in the presence of thoraco-
abdominal movements. Hypopnea was defined as a $50%
decrease in the sum of thoraco-abdominal movements lasting
$10 seconds followed by a reduction of SaO2 of $4%. The pres-
ence of PB during sleep was visually assessed.7 Specifically, the
presence of PB during sleep was visually assessed considering
PB to be an oscillatory pattern in ventilation with a period of
w60 s characterized by phases of hyperventilation and central ap-
nea or hypopnea.10 From these data we calculated the apnea/hypo-
pnea index, apnea mean duration time, mean SaO2 during sleep,
mean nadir SaO2 during sleep, and time with SaO2 !90%.Statistical Analysis
Data are presented as mean 6 SD. Analysis of variance was
used for repeated measurements. Data were reported in an Excel
data file and analyzed with SPSS software (version 10.0; SPSS,
Chicago, Illinois). Comparisons were made with the use of Stu-
dent t paired test with Bonferroni corrections for initial and final
values and for peak and nadir values, and a P value of !.05
was considered to be significant.Results
The characteristics of the 20 study patients are summa-
rized in Table 1. All were male with a mean age of 69 years
with severe HF (mean LVEF 27%, peak VO2 12.4 6 4.7
mL kg1 min1, VE/VCO2 51.7 6 7.3), and 35% had
ischemic and 65% nonischemic etiologies. Typical for the
therapy of this group, most were on beta-blockers, di-
uretics, and antiangiotensin therapies. Other medications
used in #50% of the patients included digoxin, amiodar-
one, mineralocorticoid antagonists, and acetylsalicylic
acid. Acetazolamide treatment did not influence diuresis,
body weight, or serum electrolytes. Indeed, before acetazol-
amide and at day 3, diuresis, body weight, and serum Naþ,
Kþ, and Cl were, respectively, 1,915 6 500 mL/24 h and
1,919 6 933 mL/24 h, 75 6 53 kg and 75 6 53 kg, 140 6
Fig. 3. Swing (difference between peak and nadir) of tidal volume (Vt) at constant-workload cardiopulmonary exercise test during air and
2% (top) and 1% (bottom) inhalation of CO2 in the 7 patients who performed both tests.
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0.4 meq/L, and 104 6 4 meq/L and 105 6 5 meq/L.Effects of CO2 Inhalation on PB During Exercise
VE (Table 2; Figs. 2 and 3). At rest, before constant
work rate exercise (while sitting on the bike), and during
ambient air breathing (stage 1), PB was evident in all of
the patients. With 2% CO2 inhalation (stage 2), PB disap-
peared in all but 1 case. In that patient, although PB was still
detectable, the amplitude of Vt swing (difference between
peak and nadir Vt) was markedly reduced (0.70 L during
stage 1 and 0.35 L during stage 2). After resuming air inha-
lation in stage 3, PB recurred in all patients with the same
pattern as before the CO2 challenge. Peak and nadir values
of Vt and VE measured during air inhalation (stages 1 and
3), and mean values of Vt and VE during 2% CO2 inhalation
(stage 2), when PB disappeared in the 20 patients who per-
formed the constant rate test with 2% CO2 inhalation, are
presented in Table 2. An example of PB cessation with 2%
CO2 inhalation is shown in Figure 2. CO2 inhalation wasevaluated with 1% and 2% in 7 of the 20 subjects according
to their willingness and personal availability at the end of a
long working day. When compared with 2% CO2, which
suppressed PB in all but 1 subject, only 2 subjects breathing
1% CO2 had disappearance of PB (Fig. 3). Although 1%
CO2 inhalation caused a reduction in the Vt variation, it
was less than during 2% CO2 inhalation (P 5 .010).
Gas Exchange (Table 3). Arterial blood gas values
measured at the end of each exercise stage showed a statis-
tically significant increase of PO2 by 12 6 2.6 mm Hg
and of SaO2 by 0.6 6 6.6%, with a reduction of pH by
0.02 6 2.02 (P 5 .001 for all), with 2% CO2. With 1%
CO2 breathing (n 5 7), we observed smaller similar direc-
tional changes in all values, but they did not reach statistical
significance compared with the same patients breathing
2% CO2.
Effects of Acetazolamide Administration
Data at Rest (Tables 4 and 5). No statistically signif-
icant differences were apparent in the cardiorespiratory pa-
rameters at rest (sitting on the bike) following the acute
Fig. 4. Example of a ramp-workload cardiopulmonary exercise
test in basal condition (top) and with earlier disappearance of pe-
riodic breathing after chronic administration of acetazolamide
(bottom). Cycle length and tidal volume (Vt) peak and nadir dur-
ing periodic breathing (BP) are indicated.
282 Journal of Cardiac Failure Vol. 20 No. 4 April 2014administration of acetazolamide, although VE and Vt had
suggestive upward trends. After prolonged administration
(2 g over 24 h), VE was increased significantly owing toTable 1. Patient Characteristics
n 20
Sex (M/F) 20/0
Age (y) 69.1 6 1.9
NYHA 2.9 6 9.7
LVEF (%) 27.2 6 7.9
LVDV (mL) 210.7 6 64.4
LVDVI (mL/m2) 112.6 6 30.5
BMI (kg/cm2) 24.5 6 3.33
Therapy
Beta-blockers 80%
ACE-I/ARB 80%
Diuretics 90%
Antialdosteronics 35%
Amiodarone 50%
ASA 40%
Digitalis 15%
Etiology
Ischemic 35%
Nonischemic 65%
NYHA, New York Heart Association functional class; LVEF, left ven-
tricular ejection fraction; LVDV, left ventricular diastolic volume; LVDVI,
left ventricular diastolic volume index; BMI, body mass index; ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; ASA, acetylsalicylic acid.an increase in Vt (þ0.11 6 1.13 L; P 5 .003), although
the RR was not changed significantly. Consequently, Pet-
CO2 decreased (2.59 6 9.7 mm Hg; P ! .001) and
PetO2 increased (þ4.62 6 2.43 mm Hg; P 5 .001). A
slight, but significant, reduction in HR was also observed.
No significant differences in resting VO2 and VCO2 were
detected. Acute acetazolamide generated no statistically
significant changes in any arterial blood gas parameter,
most importantly no change in HCO3
, reflecting an insuf-
ficient time for the drug to have caused any quantitative
renal bicarbonate loss. PCO2 and PO2 were slightly higher,
suggestive of a higher VE and a slight impairment of pul-
monary CO2 excretion from red cell and vascular endothe-
lial cell CA inhibition,12 but none of these changes reached
statistical significance. In contrast, prolonged acetazol-
amide generated a statistically significant metabolic
acidosis (lower pH and lower HCO3
) from renal CA inhi-
bition resulting in a greater VE and arterial PO2. SaO2 was
not increased, reflecting a right shift in the hemoglobin
dissociation curve arising from the Bohr Effect.
Data at Peak Exercise (Tables 5 and 6). All subjects
gave a full effort as indicated by achievement of a discernible
ventilatory threshold (data not shown) and a fall in HCO3
 of
3e4 mmol/L. Maximum HR was lower than age predicted
owing to the high prevalence of beta-blocker use and possibly
intrinsic chronotropic insufficiency typical in this patient
group. No differences were observed among cardiorespiratory
parameters at peak exercise after acute acetazolamide infusion
compared with the control study. However, after prolonged
administration of acetazolamide, maximum work load was
significantly reduced byw10% (P! .02). We also observed
a significant decrease in peakVO2 and peakVCO2. TotalVE at
peak exercise did not change significantly, but VE at any given
work load was higher, as reflected in the lower PetCO2 and
higher VE/VCO2 values (data not shown). After prolonged
acetazolamide, the VE/VCO2 slope increased. The arterial
blood gas values during all stages of exercise and up to peak
exercise are presented in Table 5. With acute acetazolamide
administration, PaCO2 was slightly higher and pH slightly
lower compared with no treatment. With prolonged acetazol-
amide pH and HCO3
 were statistically significantly lower
and PaO2 higher than with no treatment as well as different
from acute acetazolamide treatment, reflecting the stronger
ventilatory stimulus of the metabolic acidosis of prolonged
administration.
PB During Exercise (Table 7). In the resting condi-
tions, PB was present throughout the entire exercise in
6 patients, whereas it disappeared before the end of exercise
in the remaining 14 patients. After acute administration of
acetazolamide, PB disappeared altogether in 1 patient, and
after prolonged administration PB disappeared in 7 pa-
tients. In the patients in whom PB was still detectable, its
duration was significantly reduced after both acute and
prolonged administration. As a percentage of exercise dura-
tion, PB was present 80 6 26%, 65 6 28%, and 43 6 39%
of the time before and after acute and prolonged acetazol-
amide administration, respectively (P 5 .121 basal vs
Table 2. Constant-Workload Exercise Test During Room Air and 2% CO2 Breathing (n 5 20)
Stage 1 (Air) (n 5 20) Stage 2 (CO2), No PB (n 5 19) Stage 3 (Air) (n 5 20)
Peak Nadir Mean Peak Nadir
Vt (L) 1.18 6 0.23 0.56 6 0.16 1.29 6 0.22 1.23 6 0.21 0.71 6 0.19
VE (L/min) 27.9 6 6.3 14.6 6 4.0 33.3 6 6.4 29.5 6 6.4 18.9 6 4.6
VE, ventilation; Vt, tidal volume; PB, periodic breathing. Data reported are those recorded at minutes 4 (stage 1), 8 (stage 2), and 12 (stage 3) of the
constant-workload exercise.
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longed). Vt and VE values measured at the beginning of
loaded pedaling (peak and nadir), at PB disappearance
and as a maximum value observed throughout exercise, in
basal condition and after acute and prolonged acetazol-
amide administration, are reported in Table 7. A significant
reduction in number of PB cycles from the beginning of ex-
ercise and a significant increase in the PB cycle length
(amplitude) were detected after acute and prolonged acet-
azolamide among patients in which PB was still present.
An example of PB reduction after prolonged acetazolamide
is shown in Figure 4.
Sleep Apnea (Table 8). Polysomnographic recordings
of respiratory events during sleep were evaluatable both in
the untreated condition and after prolonged administration
of acetazolamide in 18/20 patients (in 1 patient the quality
of recording after acetazolamide was not sufficient for eval-
uation, and 1 patient was intolerant of the monitoring
equipment). In all recorded patients, significant sleep apnea
was detectable in the untreated condition; however, in 2 pa-
tients the apnea/hypopnea index was below the cutoff of 10.
The apnea/hypopnea index significantly decreased after
prolonged administration of acetazolamide, whereas the
average duration of events did not change significantly.
We also observed a significant increase of nocturnal meanTable 3. Arterial Blood Gas Ana
Stage 1 (Air) Stage 2 (CO2) Stage 3 (Air
2% CO2 (n 5 20)
pH 7.46 6 6.05 7.44 6 4.03 7.45 6 5.03
PO2 (mm Hg) 94.5 6 50.5 107.4 6 40.3 96.3 6 31.5
PCO2 (mm Hg) 36.1 6 1.9 37.2 6 2.5 36.4 6 4.6
HCO3
 (mmol/L) 26.3 6 3.1 25.8 6 8.0 26.0 6 0.2
SaO2 (%) 97.7 6 7.8 98.3 6 3.5 97.7 6 7.9
2% CO2 (n 5 7 [patients who also underwent 1% CO2])
pH 7.47 6 7.07 7.45 6 5.05 7.46 6 6.03
PO2 (mm Hg) 92.9 6 93.2 106.7 6 7.0 95.4 6 44.0
PCO2 (mm Hg) 35.4 6 4.5 35.9 6 9.5 36.1 6 1.5
HCO3
 (mmol/L) 26.3 6 3.6 25.4 6 4.3 26.2 6 2.1
SaO2 (%) 97.7 6 7.9 98.4 6 4.2 97.7 6 7.1
1% CO2 (n 5 7)
pH 7.47 6 7.05 7.45 6 5.04 7.46 6 6.04
pO2 (mm Hg) 96.6 6 60.8 100.6 6 62.1 98.9 6 90.6
pCO2 (mm Hg) 32.8 6 8.0 34.5 6 55.0 35.4 6 4.6
HCO3
 (mmol/L) 24.8 6 8.5 25.0 6 0.1 25.8 6 8.9
SaO2 (%) 98.0 6 0.7 98.1 6 1.7 98.0 6 0.7
ANOVA, analysis of variance; PO2, oxygen partial pressure; PCO2, carbon diSaO2 and of the time with SaO2!90%, whereas no differ-
ence was observed in mean nadir SaO2.Discussion
The important findings in this study are the following:
1) Inhalation of 2% CO2 during submaximal exercise
completely abolished PB during exercise in 95% of subjects
with HF, but 1% CO2 inhalation was effective in suppress-
ing PB in only one-third; 2) with 2% CO2 the subjects
reached a higher mean VE and Vt than the peak VE and
Vt of the PB cycles; 3) acetazolamide given acutely (intra-
venously) was relatively ineffective in suppressing PB dur-
ing exercise, but when given over 24 hours, long enough to
generate a metabolic acidosis, PB was suppressed in 7 pa-
tients; 4) in those patients on prolonged acetazolamide but
without PB suppression, the number of PB cycles was
reduced and the length of each cycle was increased; and
5) prolonged acetazolamide reduced exercise capacity
by w10% but improved sleep-disordered breathing with a
reduction in the apnea-hypopnea index by 28%, leading
to an overall higher mean arterial oxygenation and less
time spent below an SaO2 of 90%. These data confirm
and extend the work of others showing that changes inlysis During CO2 Inhalation
) ANOVA
Bonferroni
Stage 1 vs 2 Stage 2 vs 3 Stage 1 vs 3
!.001 .001 .208 .307
!.001 !.001 !.001 .413
.376
.437
.001 .001 .001 1.000
.267
.020 .009 .054 .524
.804
.703
.183
.373
.401
.150
.505
.444
oxide partial pressure; HCO3
, bicarbonate; SaO2, oxygen saturation.
Table 4. Ramp-Protocol CPET: Data at Rest
No therapy Acute Chronic ANOVA
Bonferroni
No Therapy vs Acute No Therapy vs Chronic Acute vs Chronic
VO2 (mL/min) 260 6 55 251 6 82 258 6 62 .87
VO2/kg (mL kg
1 min1 4.2 6 2.3 3.5 6 5.6 3.8 6 8.6 .629
VCO2 (mL/min) 203 6 36 228 6 88 225 6 54 .068
VE (L/min) 11.7 6 7.0 13.0 6 0.0 13.8 6 8.8 .001 .13 .001 .593
Vt (L) 0.56 6 6.10 0.60 6 0.09 0.67 6 7.14 .003 .075 .002 .062
PetCO2 (mm Hg) 29.4 6 4.3 28.9 6 9.4 26.8 6 8.9 !.001 1 !.001 .002
PetO2 (mm Hg) 112.9 6 9.2 114.2 6 2.5 117.5 6 5.7 .001 .673 .001 .019
RR 21.0 6 0.7 21.8 6 8.6 22.3 6 3.7 .271
HR 73 6 35 71 6 12 69 6 93 .016 .741 .019 .106
O2 pulse (mL/beat) 3.6 6 6.7 3.8 6 8.0 4.0 6 0.1 .082
ANOVA, analysis of variance; VO2, oxygen consumption; VCO2, CO2 production; VE, ventilation; Vt, tidal volume; PetCO2, end-tidal pressure of CO2;
PetO2, end-tidal pressure of O2; RR, respiratory rate (breaths/min); HR, heart rate (beats/min).
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netics act to reduce PB in HF.
The regulation of breathing by the CNS is a complex pro-
cess and arises from the medullary respiratory center, the
output of which is influenced by a variety of factors,
including cortical stimulation during the awake state,
afferent signaling from the peripheral and central chemore-
ceptors, arterial baroreceptors, lung stretch receptors,
musculoskeletal metaboreceptors, and numerous circu-
lating vasoactive mediators that are altered in HF.3 InTable 5. Effect of Acetazolamide o
Minute Basal Acute Chron
pH 0 7.47 6 7.05 7.45 6 5.04 7.42 6
2 7.47 6 7.04 7.45 6 5.04 7.42 6
4 7.46 6 6.04 7.45 6 5.04 7.42 6
6 7.46 6 6.04 7.45 6 5.03 7.41 6
8* 7.47 6 7.04 7.45 6 5.03 7.42 6
Peak 7.47 6 7.04 7.46 6 6.03 7.40 6
PO2 (mm Hg) 0 92.8 6 81.6 95.00 6 03.4 101.2 6
2 93.6 6 65.3 92.37 6 72.8 98.6 6
4 91.5 6 53.3 93.47 6 75.2 101.4 6
6 95.5 6 54.6 95.79 6 94.8 102.5 6
8* 101.2 6 24.2 102.53 6 36.2 104.3 6
Peak 102.9 6 98.3 104.57 6 77.4 107.0 6
PCO2 (mm Hg) 0 36.7 6 7.8 37.44 6 4.2 35.4 6
2 35.9 6 9.3 37.76 6 6.9 35.3 6
4 36.0 6 0.9 37.09 6 9.7 35.5 6
6 35.5 6 5.1 36.82 6 2.5 35.7 6
8* 33.0 6 0.6 35.75 6 5.2 34.3 6
Peak 32.6 6 6.9 32.96 6 6.6 34.3 6
HCO3
 (mmol/L) 0 26.8 6 8.2 26.68 6 8.1 23.3 6
2 26.6 6 6.4 26.52 6 2.1 23.2 6
4 26.3 6 3.9 26.18 6 8.0 23.4 6
6 26.0 6 2.6 26.06 6 6.5 23.2 6
8* 24.6 6 6.6 25.65 6 5.3 22.7 6
Peak 23.6 6 6.5 24.19 6 9.9 21.7 6
SaO2 (%) 0 97.5 6 5.1 97.5 6 5.0 97.92 6
2 97.3 6 3.7 97.3 6 3.0 97.69 6
4 97.3 6 3.4 97.2 6 2.7 97.88 6
6 97.5 6 5.2 97.6 6 6.0 97.82 6
8* 97.9 6 9.0 98.0 6 0.9 97.98 6
Peak 97.7 6 7.4 98.0 6 0.2 98.00 6
Abbreviations as in Table 3.
*n 5 14.addition to these tonic influences, time-dependent differ-
ences in arrival of these signals at the peripheral and central
chemoreceptors and thence to the medullary respiratory
controller also may be involved in stability or instability
in breathing.17 Of the several mechanisms postulated to
cause PB in HF, whether in sleep, wakefulness, or exercise,
alterations involving changes in CO2 have received consid-
erable attention. Experimental manipulations of CO2 and
acid-base status by CO2 inhalation (as in the present study)
and dead-space addition7 during exercise that reduce orn Arterial Blood Gas Values
ic ANOVA
Bonferroni
No Therapy vs
Acute
no Therapy vs
Chronic
Acute vs
Chronic
2.05 !.001 .58 !.001 .00
2.04 !.001 .04 !.001 .00
2.04 !.001 .25 !.001 !.001
1.04 !.001 .77 !.001 !.001
2.04 .004 .37 .003 .01
0.04 !.001 1.00 !.001 !.001
20.5 !.001 .89 !.001 .02
11.4 .008 1.00 .012 .02
41.6 .001 1.00 .001 .00
53.8 !.001 1.00 !.001 !.001
4.6 .001 1.00 .117 .00
04.6 .015 1.00 .068 .01
4.6 .09
3.1 .041 .193 1.000 .038
3.2 .118
7.4 .29
3.1 .022 .063 .881 .020
3.0 .584
2.3 !.001 1.00 !.001 !.001
2.1 !.001 1.00 !.001 !.001
2.0 !.001 1.00 !.001 !.001
2.1 !.001 1.00 !.001 !.001
7.1 !.001 .68 !.001 !.001
7.1 !.001 1.00 .004 !.001
2.7 .127
9.9 .109
8.8 .075
2.9 .067
8.9 .221
0.1 .111
Table 6. Ramp-Protocol CPET: Peak Exercise Data
No Therapy Acute Chronic ANOVA
Bonferroni
No Therapy vs
Acute
No Therapy vs
Chronic Acute vs Chronic
Work load (W) 61.3 6 32.1 58.9 6 92.0 55.9 6 90.9 .021 .311 .019 .051
Exercise tolerance (min) 9.6 6 6.6 9.2 6 2.7 8.8 6 8.8 .086
VO2 (mL/min) 920 6 019 862 6 232 849 6 908 .045 .121 .036 1
VO2/kg (mL kg
1 min1) 12.4 6 4.7 11.5 6 5.6 11.5 6 5.0 .043 .065 .054 1
VO2 % of predicted value 46 6 61 44 6 42 43 6 31 .039 .11 .032 1
VCO2 (mL/min) 945 6 541 874 6 473 836 6 622 .02 .151 .014 .627
VE (L/min) 47.4 6 4.6 43.2 6 21.4 45.7 6 7.6 .077
Vt (L) 1.33 6 3.25 1.27 6 7.25 1.39 6 9.25 .031 .516 .341 .023
PetCO2 (mm Hg) 27.6 6 6.9 26.6 6 6.7 24.3 6 3.0 !.001 .06 !.001 .001
PetO2 (mm Hg) 120.4 6 4.4 120.4 6 4.6 122.3 6 3.2 .121
RR 33.1 6 1.3 32.7 6 7.1 31.3 6 3.1 .08
HR 105 6 51 103 6 31 98 6 80 .028 1 .02 .158
O2 pulse (mL/beat) 9.4 6 4.9 8.4 6 4.2 8.8 6 8.1 .034 .477 .069 .069
VE/VCO2 at peak 51.7 6 9.3 51.0 6 9.1 56.5 6 11.8 .022 1 .026 .072
Slope
VE/VCO2 39.0 6 0.7 39.7 6 7.1 43.5 6 5.2 .022 1 .015 .12
VO2/work (mL min
1 W1) 8.9 6 9.7 9.3 6 3.7 8.9 6 9.7 .334
Abbreviations as in Tables 3 and 4.
CO2 Regulation in Periodic Breathing  Apostolo et al 285abolish PB appear to be explained well by an increase in the
eupneic PCO2 to apneic PCO2 threshold. Both maneuvers,
by raising eupneic PCO2, increase this difference and pre-
vent or minimize the potential that any period of increased
VE, by whatever stimulus, will drive arterial PCO2 below
the apneic threshold. A fall below this threshold initiates
a cessation of breathing that is ultimately ended when the
combined strong stimuli of a falling arterial PO2 and rising
arterial PCO2 evoke a brisk hyperventilatory response that
then drives the PCO2 down again below the apneic
threshold to set up a vicious cycle of PB.Effects of Inhaled CO2 on PB and Gas Exchange
Our finding that CO2 inhalation during exercise abolishes
PB in a dose-dependent manner is fully consistent with theTable 7. Effect of Acetazolamide
Basal Acute Ch
VE (L/min)
Peak (*) 22.6 6 6.9 (n 5 20) 22.0 6 0.3 (n 5 19) 20.8 6 8
Nadir (*) 8.0 6 0.6 (n 5 20) 9.6 6 6.9 (n 5 19) 8.5 6 5
Disappearance 32.8 6 80.2 (n 5 14) 28.7 6 7.4 (n 5 17) 32.2 6 2
Maximum 48.4 6 40.9 (n 5 20) 43.9 6 91.2 (n 5 19) 45.4 6 4
Vt (L)
Peak (*) 1.0 6 0.2 (n 5 20) 0.9 6 9.3 (n 5 19) 0.9 6 9
Nadir (*) 0.3 6 3.1 (n 5 20) 0.4 6 4.1 (n 5 19) 0.4 6 4
Disappearance 1.3 6 3.2 (n 5 14) 1.1 6 1.3 (n 5 17) 1.1 6 1
Maximum 1.5 6 5.2 (n 5 20) 1.4 6 4.2 (n 5 19) 1.5 6 5
No. of cycles 5.0 6 0.9 (n 5 20) 3.6 6 6.9 (n 5 19) 2.9 6 9
Length of 1st cycle
of exer. (s)
83.1 6 16 (n 5 20) 88.9 6 99.9 (n 5 19) 101.9 6 9
Abbreviations as in Table 4.
*Peak and nadir were calculated as mean value of the first 2 cycles from theparadigm that an elevation of eupneic PCO2 without a
change in the apneic PCO2 threshold will act to stabilize
breathing against a strong background of ventilatory stimu-
lation such as exists in HF. This has already been demon-
strated in these patients during sleep,8e10 and we show
for the first time the same efficacy in exercise. We also
found that arterial PO2 was significantly higher with
inhaled CO2, likely a result of both an increase in VE and
a reduction in ventilation-perfusion mismatching.18 The
tendency to PB may arise from an augmentation in the
summed chemoreceptor inputs to respiratory drive, which
are O2 (peripheral) and CO2 (peripheral and central) depen-
dent. Although the slight rise in PCO2 would be stimulating
to ventilatory drive, the concurrent rise in PO2 of 13 mm Hg
(with 2% CO2) or 4 mm Hg (with 1% CO2) may exert a
counterinhibitory effect via withdrawal of peripheralon Periodic Breathing Cycle
ronic ANOVA
Bonferroni
No Therapy vs
Acute
No Therapy vs
Chronic
Acute vs
Chronic
.3 (n 5 13) .443
.7 (n 5 13) .014 .012 .157 .604
0.7 (n 5 13) .687
2.9 (n 5 13) .248
.2 (n 5 13) .509
.1 (n 5 13) .021 .133 .014 .169
.3 (n 5 13) .427
.3 (n 5 13) .348
.9 (n 5 13) .002 0.157 .001 .18
9.6 (n 5 13) .003 1 .002 .042
beginning of exercise.
Table 8. Effect of Acetazolamide on Sleep Apnea
Basal
Chronic
Therapy P Value
Apnea/hypopnea Index
(events/h)
30.8 6 13.8 21.1 6 16.9 .003
Mean apnea duration (s) 26.9 6 6.1 28.4 6 7.0 .431
Mean SaO2 (%) 93.2 6 2.3 94.1 6 2.2 .005
Minimal SaO2 (%) (nadir) 86.6 6 2.5 86.1 6 4.6 .677
Time at SaO2 !90% (min) 65.6 6 86.1 37.1 6 54.8 .035
% of time at SaO2 !90% 12.76 6 15.5 9.6 6 15.5 .031
SaO2, oxygen saturation.
286 Journal of Cardiac Failure Vol. 20 No. 4 April 2014chemoreceptor afferent signaling. Although O2-sensitive
carotid body output is not generally thought to be important
when PaO2 is O70 mm Hg, owing to the very hyperbolic
nature of the hypoxic ventilatory response, some peripheral
chemoreceptor activity is still present at normal physiologic
PaO2 (and more so in HF patients) and can be suppressed
with further elevation of PaO2 beyond 100 mm Hg.
19
Effects of Acetazolamide on Gas Exchange, Exercise
Performance, PB, and Sleep
We found that when acetazolamide is given acutely and
patients are studied before the development of any appre-
ciable metabolic acidosis (Table 5) there is, compared
with the basal test, a statistically nonsignificant increase
in resting VE (Table 4) associated with an increase in
PaO2 as well as PaCO2. These changes reflect the mild hy-
perventilatory stimulus of slight CO2 retention arising from
partial red cell CA inhibition and complete vascular endo-
thelial cell CA inhibition12,20 that occur with the transient
high free drug levels reached with intravenous administra-
tion. The same pattern of gas exchange and increased VE
relative to CO2 production (VE/VCO2) at rest is evident
during exercise. Acute acetazolamide caused a slight reduc-
tion in peak VO2 and work load similar to that seen in
healthy subjects,21 reflecting a possible limiting effect on
exercise of a slightly higher ventilatory demand and a
greater degree of CO2 retention and acidosis at the muscle
(cardiac and skeletal) level that is not accurately reflected
by arterial blood gas values.22
The trends noted above with acute acetazolamide on gas
exchange and exercise performance were greater and
reached statistical significance with the continued oral
administration of the drug over the subsequent 24 hours.
The patients had the expected fall in bicarbonate and lower
arterial pH from renal loss of bicarbonate.12 In this situation
of lower free drug levels with oral administration and a
metabolic acidosis, VE was higher at rest and at all levels
of exercise. As a result, arterial PCO2 was decreased and
PaO2 was much higher. The lack of arterial PCO2 elevation
compared with that observed with acute intravenous admin-
istration is consistent with less red cell CA inhibition and
thus less impairment of pulmonary CO2 excretion.
22
Despite better gas exchange, peak exercise was reduced,
again likely owing to the acidosis and greater ventilatory
demand causing a greater proportion of the cardiac outputnecessary to serve the respiratory muscles and diverting
blood flow from the exercising locomotor muscles,23 as is
observed in healthy humans given acetazolamide orally
over 24 hours.24
Acetazolamide acutely and after 24 hours of administra-
tion was effective in suppressing PB during exercise, but
not as potently as 2% inhaled CO2. We chose to study
1% and 2% inhaled CO2 to recreate the slight degree of
CO2 retention expected with acetazolamide, particularly
with the acute intravenous dosing. In this respect we were
successful, because the elevations in PaCO2 with 2%
inhaled CO2 of 1.11 mm Hg (Table 3) and with acute acet-
azolamide of 1.05 mm Hg (Table 5) at roughly equivalent
exercise levels were similar. However, this was not the
case with prolonged acetazolamide, in which the PaCO2
was, in fact, lower and yet PB suppression was even greater
with chronic acetazolamide than with acute acetazolamide.
Although the slightly higher PaCO2 with acute dosing of
acetazolamide and partial suppression of PB fits with a
drug-induced widening of the eupneic-apneic PCO2 differ-
ence, the paradox of even greater PB suppression associated
with lower PaCO2 with chronic acetazolamide requires
explanation. The paradox was resolved by Nayakama
et al,25 who showed that in sleeping dogs given acetazol-
amide and studied after a metabolic acidosis was estab-
lished did widen the eupneic-apneic PCO2 difference.
This was brought about by the increased tonic hyperventi-
lation driving down the apneic PCO2 to a greater extent
than eupneic PCO2 was lowered. This was also shown for
almitrine, a nonhypoxic peripheral chemoreceptor stimu-
lant, but not for hypoxia itself.
CA is present in many tissues, including the brain and
chemoreceptors,12 and we must consider other actions by
which acetazolamide might be effective in PB suppression
both in exercise and during sleep. As mentioned above, PB
may have as one of its contributors a mismatch or temporal
dyssynchrony of inputs from the peripheral chemoreceptors
(largely O2 sensing, but also CO2/pH sensing) and the cen-
tral chemoreceptors (only CO2/pH sensing). One source of
this mismatch (a delay in the time of transit of blood from
the lungs to the chemoreceptors) could be differences in
cardiac output with acetazolamide, but studies in animals
and healthy humans show no reduction of cardiac output
at any exercise level.26,27 The other manner in which the
rate of afferent signaling might be altered relates to the ef-
fects of CA inhibition in the chemoreceptors themselves.
CA inhibitors slow the rate at which the peripheral chemo-
receptors respond to a change in pO2 and reduce the magni-
tude of the final response20,28 as well as the rate of response
to changes in CO2.
28 In similar fashion, the rate of response
to CO2 in the central chemoreceptors also is slowed
by acetazolamide.29 Slowing of these responses may be suf-
ficient enough that in the event of a random increase or
decrease in VE causing a change in PaCO2 and PaO2, the
tendency of the respiratory controller to overreact and
then underreact in response will be dampened or abolished,
such as is the case in high-altitude PB.30,31
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Our results showing PB suppression in exercise with
acetazolamide differ somewhat from those of Fontana
et al,14 who failed to find any effect, despite showing, as
we did, reduction in PB and central apneas during sleep
in these patients (see also Javaheri13) and reduction in
maximal exercise capacity. They used a lower dose of pro-
longed acetazolamide (250 mg every 12 hours for 4 days) in
contrast to our higher dosing of 500 mg every 8 hours over
24 hours. As a result, free drug levels and degree of tissue
CA inhibition were considerably higher in our patients.15
Although no arterial blood gas measurements were taken
by Fontana et al,14 we do not think the magnitude of meta-
bolic acidosis was any different, because full renal CA in-
hibition is reached at very low doses (1e2 mg/kg) owing to
drug concentration in the urine by renal tubular secretion.12
Instead, the difference in exercise PB responses must be
dependent on greater and more critical inhibition of CA
in the chemoreceptors and brain and thus require higher
doses than the lower doses of acetazolamide that are effec-
tive in suppression of sleep breathing irregularities.
The heart contains several isoforms of CA at very low
concentrations,32,33 but their roles remain uncertain given
that even under the maximal demands of heavy exercise,
there is no reduction of cardiac output26 or evidence of
reduced myocardial contractility.34 Furthermore, with
more than 5 decades of use in several chronic conditions,
such as glaucoma, there have been no reports of adverse
direct cardiac effects. In fact, more recent work suggests
that acetazolamide may prevent and reverse cardiomyocyte
hypertrophy33,35 by causing a very slight intracellular
acidosis36 that opposes the intracellular alkalizing hypertro-
phic stimulus initiated by alpha-adrenergic activation.33
This reassuring safety record would support a trial of acet-
azolamide in HF patients with PB and central sleep apnea.
The benefits, particularly during sleep, of many hours of
regular breathing might reduce neurosympathetic activation
and perhaps alter the course of myocardial hypertrophic re-
modeling and the even more relevant risk of sudden cardiac
death.37
A few study limitations should be acknowledged. First,
we strongly encouraged patients to perform a maximal
effort; however, the test was self-ended by the patients
when they felt that they had reached their maximal possible
performance. In HF patients studied with CPET, peak exer-
cise respiratory ratio (VCO2/VO2)O1.1 is used as an index
of maximal or near-maximal exercise performance. Howev-
er, with PB, the respiratory ratio is cyclic with a wide vari-
ation, so that its value at peak exercise as an index of
maximal metabolic effort has no meaning. Therefore, we
can only rely on the patient’s cooperation. Second, we stud-
ied the effects of acetazolamide for 2 days. The safety and
the effects on respiratory parameters of acetazolamide with
more chronic administration in chronic HF patients remain
unknown. Our observation should not be used to suggest
chronic treatment with acetazolamide in HF patients with
exercise PB until a proper clinical trial is conducted. Third,
we studied severe HF patients only in a stable clinicalcondition. The effects of acetazolamide administration in
patients with an unstable clinical state or with relevant clin-
ical comorbidities, such as lung disease or renal failure, is
also unknown.
In conclusion, we have shown for the first time that both
inhaled CO2 and acetazolamide favorably alter PB during
exercise in HF patients, and we add further to the evidence
of a benefit of acetazolamide during sleep. The mechanism
of action of both inhaled CO2 and acetazolamide to reduce
PB involves increasing the eupneic-apneic PCO2 difference
so that any spontaneous variability of VE does not so easily
drive arterial PCO2 below the apneic threshold. Further-
more, acetazolamide may also act to stabilize breathing
by slowing the response dynamics of chemoreceptor
signaling to the respiratory control center and so reduce
the tendency of overresponse to small fluctuations in arte-
rial PCO2 and PO2. Our findings and those of others suggest
that whether breathing is stabilized or destabilized in HF
patients is a complicated scenario dependent on the causes
of background heightened ventilatory drive, the prevailing
arterial and tissue partial PCO2 and PO2, and the speed at
which changes in these gas values are sensed at sites of
chemoreception, signaled, and then processed at the respi-
ratory control center.Disclosures
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